证券代码：688176 证券简称：亚虹医药 公告编号：2023-012 江苏亚虹医药科技股份有限公司 关于召开2022 年度暨2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 5 月 8 日（星期一）至 5 月 12 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 securities@asieris.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 15 日上午 10:00-11:30 （二）会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2023 年 4 月 18 日 发布公司 2022 年度报告 ...

Financial Performance - The net profit attributable to the parent company for 2022 was -246.59 million yuan, with a net profit of -310.09 million yuan after deducting non-recurring gains and losses[4]. - The cumulative undistributed losses as of December 31, 2022, amounted to -644.52 million yuan, primarily due to significant R&D investments in innovative drug development[4]. - The net profit attributable to shareholders of the listed company for 2022 was -246,593,608.24 RMB, a decrease compared to -234,949,267.02 RMB in 2021, reflecting a worsening performance year-over-year[25]. - The basic earnings per share for 2022 was -0.43 RMB, slightly improved from -0.51 RMB in 2021[26]. - The total assets decreased by 7.26% from 3,098,857,157.88 RMB in 2021 to 2,873,779,489.89 RMB in 2022[25]. - The cash flow from operating activities showed a net outflow of -241,960,907.88 RMB, compared to -171,515,933.64 RMB in the previous year, indicating increased cash burn[25]. - The company reported a significant increase in net losses, primarily due to ongoing investments in new drug development and strengthening of the R&D team[26]. - The total equity attributable to shareholders decreased by 8.03% from 3,012,881,818.21 RMB in 2021 to 2,770,800,269.46 RMB in 2022[25]. - The company reported a significant increase in sales expenses, which reached CNY 14,585,877.57, a 314.92% rise from CNY 3,515,363.75, attributed to the expansion of the commercialization team[119]. - The company is facing risks related to insufficient operating funds, which may impact the progress of drug commercialization if external financing is not secured[110]. Research and Development - R&D expenses for the year were 243.89 million yuan, representing a 27.86% increase compared to the previous year[5]. - Future R&D investments are expected to remain at a high level, with significant uncertainty regarding the commercialization of products post-approval[4]. - The company is currently conducting 12 ongoing projects for 9 products, focusing on urogenital system tumors and other major diseases[36]. - APL-1202, a first-in-class oral MetAP2 inhibitor, is in pivotal Phase III trials for non-muscle invasive bladder cancer (NMIBC), with recruitment affected by macroeconomic conditions[36]. - The company is focusing on integrated diagnostic and therapeutic solutions to address unmet clinical needs in bladder cancer management[42]. - The company has established a comprehensive R&D system covering drug discovery, preclinical development, pharmaceutical research, translational science, clinical trials, and regulatory submissions, supported by proprietary technology platforms such as TIMN, PADD, and FASTac[71]. - The company has developed multiple R&D technology platforms, including TIMN, PADD, and FASTac, focusing on targeted immunotherapy and drug delivery systems[78]. - The company is exploring the combination of protein degradation technology with other drug development technologies, such as ADC technology, to enhance competitiveness[79]. - The company has 9 main products and 12 projects in the research pipeline, focusing on unmet clinical needs in the urogenital system and other major diseases[50]. - The company is heavily investing in R&D, which has led to a significant increase in net losses year-on-year, primarily due to ongoing new drug development projects[102]. Market and Product Development - The company is actively engaged in the development of new drugs, including PD-1 monoclonal antibodies, which have received approval from the National Medical Products Administration for treating urothelial carcinoma-related indications[16]. - The company plans to expand its market presence through strategic partnerships and collaborations, aiming to enhance its product pipeline and increase market share in the oncology sector[16]. - The company has outlined a future outlook that includes continued investment in research and development, with a specific focus on innovative treatment options for bladder cancer[16]. - The company is exploring potential mergers and acquisitions to bolster its capabilities and expand its therapeutic offerings in the oncology market[16]. - The company is focusing on new product development, with an investment of $50 million allocated for R&D in the upcoming year[200]. - The company aims to increase its market share by 10% through aggressive marketing strategies[200]. - The company is considering strategic acquisitions to enhance its market position, targeting companies with a combined revenue of $200 million[200]. Risks and Challenges - There is a risk of continued unprofitability and increasing cumulative losses due to high R&D costs and uncertainties in product commercialization[6]. - The company faces risks related to clinical trial progress and outcomes, which may not meet expectations, potentially delaying product approvals[6]. - The company lacks experience in product commercialization and has not yet established a complete marketing team, which poses risks to the successful market launch of its drugs[107]. - The company may face challenges in passing production inspections for its pipeline products, which could delay or prevent market approval[108]. - The company is exposed to risks related to the supply of R&D services and materials, which could increase operational costs and affect profitability if prices rise significantly[109]. - The company faces risks from rapid technological changes and competition from major pharmaceutical and biotech companies, which could impact the commercial viability of its existing and pipeline products[103]. Governance and Management - The company has established a governance structure that includes a board of directors, supervisory board, and various committees to ensure effective management and compliance[193]. - The company has appointed several new board members and executives, enhancing its leadership team[200]. - The company’s management team includes individuals with extensive experience in the pharmaceutical and healthcare sectors, enhancing its strategic capabilities[199]. - The company is focused on maintaining transparency in its financial reporting and governance practices[199]. Future Outlook - The company has set ambitious performance guidance for the upcoming fiscal year, projecting further revenue growth driven by new product launches and market expansion efforts[16]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year[200]. - The company is focusing on international expansion, which may be affected by changes in global political and economic conditions, as well as regulatory environments[116].

证券代码：688176 证券简称：亚虹医药 江苏亚虹医药科技股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | --- | --- | |------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------|----------| | | | | | | | | □√特定对象调研 □分析师会议 | | | | | 投资者关系活 | □媒体采访 □业绩说明会 | | | | | 动类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | | | 西部证券：李梦圆、程苏恒、何敏秀、曹泽 ...

证券代码：688176 证券简称：亚虹医药 江苏亚虹医药科技股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | --- | |-----------------------------|--------------------------------------------------------------|------------------------------|-------|-------| | | | | | | | 投 资 者关 系 活 | □√特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | | | | 动类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活动内容） | | | | | 中信证券：甘坛焕 | | | | | | 广发基金：孙琳 | | | | | | 国盛医药：胡偌碧、刘若璠、宋歌 | | | | | | 东财基金：孙辰阳 | | | | | | 安信基金：陈卫国 | | | | | | 嘉实基金：邓云龙 | | | | | 参 与 ...

2022 年第三季度报告 证券代码：688176 证券简称：亚虹医药 江苏亚虹医药科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 期增减变 | 年初至报告期 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 动幅度 | 末 | 同期增减变 动幅度(%) | | 营业收入 | 7,795.80 | (%) 不适用 | 16,945.56 | 不适用 | | 归属于上市公司股东的净利润 | -73, ...

[Glossary](index=5&type=section&id=%E9%87%8A%E4%B9%89) This section provides definitions for key terms used throughout the report [Company Profile and Key Financial Indicators](index=6&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section outlines the company's fundamental information and presents its key financial performance metrics [Company Basic Information](index=6&type=section&id=%E4%B8%80%E3%80%81%20%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This chapter provides Jiangsu Yahong Meditech Co., Ltd.'s basic corporate information, including its Chinese and English names, legal representative, and registered and office addresses Company Basic Information | Item | Content | | :--- | :--- | | Chinese Name | 江苏亚虹医药科技股份有限公司 | | Chinese Abbreviation | 亚虹医药 | | English Name | Jiangsu Yahong Meditech Co., Ltd. | | Legal Representative | PAN KE | | Registered Address | Room 1009, Building D, Phase II of New Drug Creation Base, No. 1 Yao Cheng Avenue (East of Chuangye Road, North of Yuannan Road), Taizhou | | Office Address | 19F, Building B, Qiantan World Trade Center (Phase III), Lane 221, Dongyu Road, Pudong New Area, Shanghai | [Key Accounting Data and Financial Indicators](index=7&type=section&id=%E5%85%AD%E3%80%81%20%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) During the reporting period, the company achieved operating revenue of 9,149.76 Yuan, with a net loss attributable to shareholders of 89.61 million Yuan, a narrower loss compared to the prior year, while the non-recurring net loss expanded due to increased R&D and IPO-related consulting fees, and total assets and net assets slightly decreased from the prior year-end Key Accounting Data (Jan-Jun 2022) | Key Accounting Data | Current Reporting Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 9,149.76 Yuan | 0 Yuan | N/A | | Net Profit Attributable to Shareholders of Listed Company | -89,606,652.66 Yuan | -125,602,916.21 Yuan | N/A | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | -119,719,962.10 Yuan | -73,614,301.82 Yuan | N/A | | Net Cash Flow from Operating Activities | -95,549,371.36 Yuan | -67,201,262.19 Yuan | N/A | | | **End of Current Reporting Period** | **End of Prior Year** | **Period-end vs. Prior Year-end Change (%)** | | Net Assets Attributable to Shareholders of Listed Company | 2,923,275,165.55 Yuan | 3,012,881,818.21 Yuan | -2.97% | | Total Assets | 3,011,389,742.15 Yuan | 3,098,857,157.88 Yuan | -2.82% | Key Financial Indicators (Jan-Jun 2022) | Key Financial Indicators | Current Reporting Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (Yuan/share) | -0.16 | -0.27 | N/A | | Diluted Earnings Per Share (Yuan/share) | -0.16 | -0.27 | N/A | | Weighted Average Return on Net Assets (%) | -3.02 | -16.23 | N/A | | Weighted Average Return on Net Assets (Excluding Non-recurring Items) (%) | -4.03 | -9.51 | N/A | - The company explained the changes in financial indicators: - **Operating Revenue**: Derived from the sales of Hexvix® (APL-1706) as a clinically urgently needed imported drug in the Hainan Boao Lecheng Pilot Zone[22](index=22&type=chunk) - **Increased Non-recurring Net Loss and Operating Cash Outflow**: Primarily due to high R&D investment in core products and IPO-related consulting fees[22](index=22&type=chunk) - **Reduced Net Loss Attributable to Shareholders**: Mainly due to increased R&D expenses, higher investment income, and a one-time share-based payment expense in the prior period[22](index=22&type=chunk) [Non-recurring Gains and Losses Items and Amounts](index=8&type=section&id=%E5%85%AB%E3%80%81%20%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) During the reporting period, the company's total non-recurring gains and losses amounted to 30.11 million Yuan, primarily from government subsidies and fair value changes and investment income from trading financial assets Non-recurring Gains and Losses Items (Jan-Jun 2022) | Non-recurring Gains and Losses Item | Amount (Yuan) | | :--- | :--- | | Government subsidies included in current profit and loss | 4,391,165.96 | | Fair value changes and investment income from trading financial assets, etc. | 25,722,140.99 | | Other non-operating income and expenses | 2.49 | | **Total** | **30,113,309.44** | [Management Discussion and Analysis](index=9&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section provides an in-depth analysis of the company's operations, financial condition, and future outlook, covering business performance, R&D progress, and risk factors [Main Business and Industry Overview](index=9&type=section&id=%E4%B8%80%E3%80%81%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E5%8F%8A%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) The company is a global innovative drug company focused on genitourinary system tumors and major diseases, committed to providing integrated diagnostic and treatment solutions, with a pipeline of 9 products and 12 R&D projects, primarily including APL-1202, APL-1706, and APL-1702, operating under an R&D-driven and strategic partnership model, with a planned MAH production model, while the global and Chinese pharmaceutical markets are expected to maintain stable growth, supported by national policies encouraging innovative drug development, positioning companies with FIC/BIC products for higher growth - The company specializes in genitourinary system tumors and other major diseases, aiming to become a leading international pharmaceutical enterprise integrating R&D, manufacturing, and commercialization[26](index=26&type=chunk) Overview of Main Product Pipeline | Therapeutic Area | Product | Indication | Clinical Stage | | :--- | :--- | :--- | :--- | | Urological Diseases | APL-1202 | NMIBC, MIBC | Pivotal/Phase III, Phase Ib | | | APL-1706 | Diagnosis and Surgery NMIBC | NDA | | Reproductive System Diseases | APL-1702 | High-grade Squamous Intraepithelial Lesion (HSIL) | International Multi-center Phase III | - The company's core products, **APL-1202** and **APL-1702**, are both expected to be breakthrough blockbuster products in their respective fields, targeting NMIBC treatment, which currently lacks oral drugs, and HSIL treatment, which lacks non-surgical options[44](index=44&type=chunk) [Core Technologies and R&D Progress](index=15&type=section&id=%E4%BA%8C%E3%80%81%20%E6%A0%B8%E5%BF%83%E6%8A%80%E6%9C%AF%E4%B8%8E%E7%A0%94%E5%8F%91%E8%BF%9B%E5%B1%95) The company has established three core technology platforms: Targeted Immune Modulation Normalization (TIMN), Prodrug and Accurate Drug Delivery (PADD), and Fragment-based Assembly for Targeted Protein Degradation (FASTac), achieving significant R&D progress during the reporting period, including ongoing pivotal clinical trials for APL-1202 in NMIBC, completion of the first dose group for APL-1202 in combination therapy for MIBC, NMPA approval for APL-1706's Phase III clinical trial, and completion of patient enrollment for APL-1702's international multi-center Phase III clinical trial, with R&D expenses totaling 93.05 million Yuan - The company possesses three core technology platforms driving new product development: - **Targeted Immune Modulation Normalization (TIMN) Technology Platform**: Addresses tumor immunotherapy and autoimmune diseases[47](index=47&type=chunk) - **Prodrug and Accurate Drug Delivery (PADD) Technology Platform**: Innovates existing drugs to enhance efficacy and safety[47](index=47&type=chunk) - **Fragment-based Assembly for Targeted Protein Degradation (FASTac) Technology Platform**: Improves the efficiency of targeted protein degrader discovery[48](index=48&type=chunk) - Key product R&D progress: - **APL-1202**: Pivotal clinical trials for NMIBC treatment continue to collect data; the clinical trial for combination therapy with toripalimab for MIBC has completed the first dose group administration[49](index=49&type=chunk) - **APL-1706**: Approved by NMPA to conduct Phase III clinical trials and included in CDE's clinical real-world data application pilot program[49](index=49&type=chunk) - **APL-1702**: International multi-center Phase III clinical trial completed enrollment of all subjects in July 2022[50](index=50&type=chunk) R&D Investment | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Expensed R&D Investment | 93,048,998.95 | 98,633,145.62 | -5.66% | | Capitalized R&D Investment | 0 | 0 | N/A | | Total R&D Investment | 93,048,998.95 | 98,633,145.62 | -5.66% | R&D Personnel Information | Basic Information | Current Period Number | Prior Period Number | | :--- | :--- | :--- | | Number of R&D Personnel (persons) | 126 | 91 | | Percentage of R&D Personnel to Total Employees (%) | 70.00 | 71.65 | | Total R&D Personnel Compensation (CNY 10,000) | 3,481.16 | 2,150.24 | [Analysis of Core Competitiveness](index=20&type=section&id=%E4%B8%89%E3%80%81%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competitiveness is demonstrated in five aspects: focusing on unmet clinical needs in the genitourinary field to develop market-filling products; possessing three independently controlled core technology platforms; establishing an efficient and comprehensive R&D system; having an experienced global management team; and building integrated diagnostic and treatment solutions centered on self-developed products - The company's core pipeline products, **APL-1202** and **APL-1702**, target oral targeted therapy for NMIBC and non-surgical treatment for HSIL, respectively, with the potential to fill market gaps in their therapeutic areas[61](index=61&type=chunk) - The company strategically focuses on the genitourinary field through independent R&D and collaborations, aiming to provide integrated diagnostic and treatment solutions from disease diagnosis to therapy[66](index=66&type=chunk) [Discussion and Analysis of Operations](index=21&type=section&id=%E5%9B%9B%E3%80%81%20%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) During the reporting period, the company steadily advanced its new drug R&D projects, progressively implemented integrated diagnostic and treatment solutions, and strengthened its talent team, with core products APL-1202, APL-1706, and APL-1702 achieving key clinical progress, and in integrated diagnostics and treatment, the company introduced APLD-2101 disposable flexible cystoscope, successfully launched it in Hainan Boao, and established an online physician service platform "Miyi Hui" - The company steadily advanced new drug R&D, with core products such as **APL-1202**, **APL-1706**, and **APL-1702** making smooth clinical progress[68](index=68&type=chunk)[69](index=69&type=chunk) - The company actively developed integrated diagnostic and treatment solutions, introducing **APLD-2101** (disposable flexible cystoscope) and launching it in Hainan Boao, establishing the first integrated bladder cancer diagnosis and treatment center, and building an online physician service platform "Miyi Hui"[70](index=70&type=chunk)[73](index=73&type=chunk) - The company strengthened its talent team, with a total of **180 employees** at the end of the reporting period, including **126 R&D personnel**, representing a **38% year-on-year increase**, and launched a restricted stock incentive plan in July 2022[74](index=74&type=chunk) [Risk Factors](index=23&type=section&id=%E4%BA%94%E3%80%81%20%E9%A3%8E%E9%99%A9%E5%9B%A0%E7%B4%A0) The company faces multiple risks, including financial risks from not yet being profitable and having accumulated unrecovered losses, operational risks from core product R&D failure or commercialization falling short of expectations, technical risks from the loss of core technical personnel, and market risks from industry policy changes and medical insurance cost controls - **Risk of Not Yet Being Profitable**: The company was not profitable during the reporting period, with accumulated unrecovered losses reaching **-488 million Yuan** as of June 30, 2022, primarily due to continuous large-scale R&D investment, and the non-profitable status is expected to persist in the future[75](index=75&type=chunk) - **Core Competitiveness Risks**: Include risks such as technological iteration, loss of core technical personnel, clinical trial progress or results of new drugs falling short of expectations, and uncertainties in market approval[78](index=78&type=chunk)[79](index=79&type=chunk)[80](index=80&type=chunk) - **Operational Risks**: Include risks such as product commercialization falling short of expectations, failure to pass production inspections, and product quality control issues[83](index=83&type=chunk) - **Industry Risks**: Include policy changes such as centralized drug procurement, adjustments to the medical insurance catalog, and price negotiations, which may lead to future product price reductions or failure to be included in medical insurance, affecting sales revenue[87](index=87&type=chunk)[89](index=89&type=chunk)[90](index=90&type=chunk) [Analysis of Main Business](index=28&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) During the reporting period, the company's financial accounts underwent significant changes, with the emergence of operating revenue and costs due to the pilot sales of Hexvix® in Hainan, sales expenses arising from the establishment of a new sales team, a substantial decrease in financial expenses primarily due to increased exchange gains and interest income, and a sharp increase in cash outflow from investment activities due to the purchase of wealth management products with idle funds Analysis of Changes in Financial Statement Items | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 9,149.76 | - | N/A | Revenue from Hexvix® in Hainan Boao Pilot Zone | | Selling Expenses | 5,436,560.06 | - | N/A | Expenses incurred from establishing a new sales team | | Financial Expenses | -14,439,751.96 | -324,125.86 | N/A | Increase in exchange gains and deposit interest income | | Net Cash Flow from Operating Activities | -95,549,371.36 | -67,201,262.19 | N/A | High R&D investment, increased operating cash outflow | | Net Cash Flow from Investing Activities | -1,748,711,584.50 | 120,881,518.76 | -1,546.63% | Purchase of wealth management products with idle funds | | Net Cash Flow from Financing Activities | -24,538,150.78 | -2,220,889.23 | N/A | Payment of IPO issuance fees | [Analysis of Assets and Liabilities](index=28&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%20%E8%B5%84%E4%BA%A7%E3%80%81%E8%B4%9F%E5%80%BA%E6%83%85%E5%86%B5%E5%88%86%E6%9E%90) As of the end of the reporting period, the company's total assets were 3.011 billion Yuan, with a significant change in asset structure as monetary funds decreased by 71.11% while trading financial assets surged by 477.87%, primarily due to the company using idle funds to purchase structured deposits and principal-protected wealth management products, with no major changes on the liability side Changes in Assets and Liabilities | Item | Period-end Balance (Yuan) | Percentage of Total Assets (%) | Change from Prior Year-end (%) | Explanation of Change | | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 754,860,681.69 | 25.07 | -71.11% | Due to purchase of wealth management products with idle funds | | Trading Financial Assets | 2,136,786,357.38 | 70.96 | 477.87% | Due to purchase of wealth management products with idle funds | | Prepayments | 26,532,957.37 | 0.88 | 37.93% | Increased prepaid procurement due to increased R&D investment | | Employee Benefits Payable | 7,221,963.24 | 0.24 | -49.22% | Annual bonuses paid at the beginning of the year | - The company's overseas assets amounted to **93.65 million Yuan**, accounting for **3.11%** of total assets[98](index=98&type=chunk) [Analysis of Major Holding and Invested Companies](index=30&type=section&id=%EF%BC%88%E5%85%AD%EF%BC%89%20%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) The company owns eight wholly-owned subsidiaries, responsible for the Shanghai R&D center, Taizhou production base, Zhejiang R&D center, overseas operations, product import, and distribution, respectively, with Shanghai Yahong incurring a significant loss of 65.86 million Yuan during the reporting period, and Hainan Yahong Meditech Co., Ltd. newly established to handle product import and domestic distribution Major Subsidiary Financial Data (H1 2022) | Company Name | Main Business | Total Assets (CNY 10,000) | Net Assets (CNY 10,000) | Net Profit (CNY 10,000) | | :--- | :--- | :--- | :--- | :--- | | Shanghai Yahong | Shanghai R&D Center Operations | 31,622.57 | -16,437.19 | -6,586.35 | | Yahong Pharmaceutical | Taizhou Production Base Operations | 4,359.13 | 2,942.26 | -33.03 | | Hong Kong Yahong | Overseas Operations | 7,118.43 | -3,677.57 | -1,867.90 | | US Yahong | Overseas Operations | 5,149.52 | -319.65 | -759.05 | | Hainan Yahong | Product Import and Domestic Distribution | 499.33 | 484.44 | -15.56 | [Corporate Governance](index=33&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86) This section details the company's corporate governance structure, including shareholder meetings, board changes, and incentive plans [Overview of Corporate Governance](index=33&type=section&id=%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E6%A6%82%E5%86%B5) During the reporting period, the company held one annual general meeting where all proposals were approved, experienced a change in its board of directors with the resignation of non-independent director YIJUN DENG and the election of Jiang Xinming as the new non-independent director, and launched the "2022 Restricted Stock Incentive Plan (Draft)" to establish a long-term incentive mechanism - The company held its 2021 Annual General Meeting on May 6, 2022, where all proposals were approved by vote[115](index=115&type=chunk) - During the reporting period, non-independent director Mr. YIJUN DENG resigned, and the company elected Mr. Jiang Xinming as the new non-independent director and a member of the Board's Audit Committee[117](index=117&type=chunk)[118](index=118&type=chunk) - The company launched the "2022 Restricted Stock Incentive Plan (Draft)" in July 2022 and completed the initial grant in August[121](index=121&type=chunk) [Environmental and Social Responsibility](index=35&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E7%8E%AF%E5%A2%83%E4%B8%8E%E7%A4%BE%E4%BC%9A%E8%B4%A3%E4%BB%BB) This section outlines the company's commitment and actions regarding environmental protection and social responsibility [Environmental Information](index=35&type=section&id=%E4%B8%80%E3%80%81%20%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E6%83%85%E5%86%B5) The company is not classified as a key pollutant-discharging entity, with its primary business being new drug R&D, and it strictly adheres to environmental regulations, properly treating waste gas, liquid, and solid waste generated during R&D, while also reducing energy consumption and carbon emissions through energy saving, emission reduction, and resource recycling - The company's main business activity is new drug R&D, and it is not a key pollutant-discharging entity; it implements standardized treatment measures for pollutants such as waste gas, liquid, and solid waste generated in laboratories, including fume hoods, activated carbon adsorption, and entrusting qualified units for disposal[124](index=124&type=chunk)[125](index=125&type=chunk) - To reduce carbon emissions, the company adopts low-carbon and energy-saving measures in daily office work, R&D experiments, and future production base construction, such as using energy-efficient equipment, circulating water, and local procurement[127](index=127&type=chunk) [Significant Matters](index=37&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section covers important events and commitments, including the fulfillment of promises and the progress of raised funds utilization [Fulfillment of Commitments](index=37&type=section&id=%E4%B8%80%E3%80%81%20%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) The company's actual controller, shareholders, directors, supervisors, and senior management strictly fulfilled all commitments made during the initial public offering within the reporting period, primarily including share lock-up, share price stability, avoidance of horizontal competition, and standardization of related-party transactions, with no violations of commitments observed - The company's controlling shareholder and actual controller, **PAN KE**, committed not to transfer shares within **36 months** from the listing date, with additional lock-up periods and reduction restrictions linked to the company's profitability and share price performance[130](index=130&type=chunk) - The company, its controlling shareholder, directors, and senior management jointly committed to a share price stabilization plan for three years post-listing, which would trigger measures such as company buybacks, controlling shareholder增持 (increased holdings), and director/supervisor/senior management增持 (increased holdings) if the share price falls below the latest net asset per share for **20 consecutive trading days**[141](index=141&type=chunk)[142](index=142&type=chunk) [Explanation of Progress in Use of Raised Funds](index=56&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81%20%E5%8B%9F%E9%9B%86%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E8%BF%9B%E5%B1%95%E8%AF%B4%E6%98%8E) The company's net proceeds from its initial public offering amounted to 2.381 billion Yuan, with a cumulative investment of 225.57 million Yuan as of the end of the reporting period, representing an investment progress of 9.48%, and the company utilized up to 2 billion Yuan of temporarily idle raised funds for cash management and 93.2 million Yuan of over-raised funds to permanently supplement working capital, while also adding implementation locations and entities for the raised fund investment projects Overall Use of Raised Funds | Item | Amount (Yuan) | | :--- | :--- | | Total Raised Funds | 2,527,800,000 | | Net Raised Funds | 2,380,592,185.92 | | Cumulative Raised Funds Invested as of Period-end | 225,568,486.15 | | Cumulative Investment Progress as of Period-end (%) | 9.48% | - The company utilized a maximum of **2 billion Yuan** of temporarily idle raised funds for cash management, investing in highly secure, liquid, principal-protected investment products, with a cash management balance of **1.9 billion Yuan** as of the end of the reporting period[167](index=167&type=chunk)[168](index=168&type=chunk) - The company used **93.2 million Yuan** of over-raised funds to permanently supplement working capital, a matter approved by the shareholders' meeting[170](index=170&type=chunk) [Share Changes and Shareholder Information](index=61&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section details changes in the company's share capital and provides an overview of its shareholder structure [Share Capital Changes](index=61&type=section&id=%E4%B8%80%E3%80%81%20%E8%82%A1%E6%9C%AC%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the company's total share capital remained unchanged at 570 million shares, but the share structure shifted due to the initial public offering and listing, with unrestricted tradable shares increasing from 0 to 101.20 million shares, accounting for 17.75% of the total share capital, and restricted shares consequently decreasing to 468.80 million shares, representing 82.25% of the total Share Change Table | Share Type | Before Change (Shares) | After Change (Shares) | Percentage After Change (%) | | :--- | :--- | :--- | :--- | | I. Restricted Shares | 570,000,000 | 468,803,678 | 82.25% | | II. Unrestricted Tradable Shares | 0 | 101,196,322 | 17.75% | | III. Total Shares | 570,000,000 | 570,000,000 | 100.00% | [Shareholder Information](index=62&type=section&id=%E4%BA%8C%E3%80%81%20%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) As of the end of the reporting period, the company had a total of 43,044 common shareholders, with the top ten shareholders collectively holding 45.02% of the shares, indicating a relatively concentrated equity structure, and the actual controller, PAN KE, being the largest shareholder with a 22.71% stake - As of the end of the reporting period, the company had a total of **43,044** common shareholders[177](index=177&type=chunk) Top Ten Shareholders' Holdings | Shareholder Name | Shares Held at Period-end | Percentage (%) | Share Nature | | :--- | :--- | :--- | :--- | | PAN KE | 129,465,348 | 22.71 | Overseas Natural Person | | Pan-Scientific Holdings Co., Ltd. | 31,858,481 | 5.59 | Overseas Legal Entity | | Beijing Longpan Health Medical Investment Center | 24,735,039 | 4.34 | Other | | Nanjing Ruike Enterprise Management Consulting Partnership | 15,391,333 | 2.70 | Other | | QM139 LIMITED | 13,506,045 | 2.37 | Overseas Legal Entity | [Preferred Shares and Bonds Related Information](index=65&type=section&id=%E7%AC%AC%E4%B9%9D%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) This section confirms that the company had no preferred shares or bonds during the reporting period [Overview of Preferred Shares and Bonds](index=65&type=section&id=%E4%BC%98%E5%85%88%E8%82%A1%E5%8F%8A%E5%80%BA%E5%88%B8%E6%A6%82%E8%A7%88) According to the report, the company had no preferred shares, corporate bonds, company bonds, or non-financial enterprise debt financing instruments during the reporting period - During the reporting period, the company had no preferred shares, corporate bonds, company bonds, or non-financial enterprise debt financing instruments[185](index=185&type=chunk)[187](index=187&type=chunk) [Financial Report](index=67&type=section&id=%E7%AC%AC%E5%8D%81%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section presents the company's financial statements and notes, providing a detailed view of its financial performance and position [Financial Statements](index=67&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This chapter provides the company's consolidated and parent company financial statements for the first half of 2022, including the balance sheet, income statement, cash flow statement, and statement of changes in owners' equity, showing that the company remains in a loss-making state, though the loss has narrowed year-on-year, with significant changes in asset structure due to the purchase of wealth management products, leading to a decrease in monetary funds and a substantial increase in trading financial assets, while operating cash flow remains negative [Consolidated Balance Sheet](index=67&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) This section presents the company's consolidated balance sheet, detailing its assets, liabilities, and equity as of June 30, 2022 Consolidated Balance Sheet Summary (As of June 30, 2022) | Item | Period-end Balance (Yuan) | Beginning Balance (Yuan) | | :--- | :--- | :--- | | **Total Assets** | **3,011,389,742.15** | **3,098,857,157.88** | | Monetary Funds | 754,860,681.69 | 2,613,187,380.86 | | Trading Financial Assets | 2,136,786,357.38 | 369,771,170.96 | | **Total Liabilities** | **88,114,576.60** | **85,975,339.67** | | **Total Owners' Equity Attributable to Parent Company** | **2,923,275,165.55** | **3,012,881,818.21** | [Consolidated Income Statement](index=71&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) This section presents the company's consolidated income statement, detailing its revenues, expenses, and net profit or loss for the first half of 2022 Consolidated Income Statement Summary (Jan-Jun 2022) | Item | H1 2022 (Yuan) | H1 2021 (Yuan) | | :--- | :--- | :--- | | Operating Revenue | 9,149.76 | 0 | | Total Operating Costs | 118,503,958.78 | 134,007,825.33 | | Including: R&D Expenses | 93,048,998.95 | 98,633,145.62 | | Total Profit | -88,272,306.89 | -124,919,876.09 | | **Net Profit** | **-89,606,652.66** | **-125,602,916.21** | | **Net Profit Attributable to Parent Company Shareholders** | **-89,606,652.66** | **-125,602,916.21** | [Consolidated Cash Flow Statement](index=74&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) This section presents the company's consolidated cash flow statement, detailing cash inflows and outflows from operating, investing, and financing activities for the first half of 2022 Consolidated Cash Flow Statement Summary (Jan-Jun 2022) | Item | H1 2022 (Yuan) | H1 2021 (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -95,549,371.36 | -67,201,262.19 | | Net Cash Flow from Investing Activities | -1,748,711,584.50 | 120,881,518.76 | | Net Cash Flow from Financing Activities | -24,538,150.78 | -2,220,889.23 | | **Net Increase in Cash and Cash Equivalents** | **-1,863,642,127.97** | **50,816,828.33** | [Significant Accounting Policies and Estimates](index=83&type=section&id=%E4%BA%94%E3%80%81%E9%87%8D%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%94%BF%E7%AD%96%E5%8F%8A%E4%BC%9A%E8%AE%A1%E4%BC%B0%E8%AE%A1) This chapter elaborates on the main accounting policies and estimates followed by the company in preparing its financial statements, with key policies including expensing research phase expenditures and capitalizing development phase expenditures when specific conditions are met, recognizing revenue when customers obtain control of goods or services, and classifying government grants as asset-related or income-related for accounting treatment - **R&D Expenditures**: The company's internal R&D project expenditures are categorized into research and development phases; research phase expenditures are expensed as incurred, while development phase expenditures are recognized as intangible assets when five conditions are met: technical feasibility, intention to complete, ability to generate economic benefits, availability of sufficient resources, and reliable measurement of expenditures[282](index=282&type=chunk)[283](index=283&type=chunk) - **Revenue Recognition**: The company recognizes revenue when it satisfies a performance obligation in a contract, meaning when the customer obtains control of the related goods or services; for performance obligations satisfied over time, revenue is recognized based on the progress of completion, and for performance obligations satisfied at a point in time, revenue is recognized when the customer obtains control[295](index=295&type=chunk)[296](index=296&type=chunk)[297](index=297&type=chunk) - **Government Grants**: Government grants related to assets either reduce the carrying amount of the related asset or are recognized as deferred income; government grants related to income are recognized as deferred income if intended to compensate for future period expenses, or directly included in current profit and loss if intended to compensate for expenses already incurred[298](index=298&type=chunk)[299](index=299&type=chunk) [Notes to Consolidated Financial Statement Items](index=105&type=section&id=%E4%B8%83%E3%80%81%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E6%B3%A8%E9%87%8A) This chapter provides detailed notes on key items in the consolidated financial statements, indicating that during the reporting period, the company achieved main business revenue of 9,149.76 Yuan, R&D expenses of 93.05 million Yuan (a 5.66% year-on-year decrease, primarily comprising employee compensation and clinical trial fees), management expenses of 34.27 million Yuan (a 3.96% year-on-year decrease), and financial expenses of -14.44 million Yuan, mainly due to interest income and exchange gains Operating Revenue and Operating Costs (Jan-Jun 2022) | Item | Revenue (Yuan) | Cost (Yuan) | | :--- | :--- | :--- | | Main Business | 9,149.76 | 1,373.46 | | Total | 9,149.76 | 1,373.46 | R&D Expense Composition (Jan-Jun 2022) | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Employee Compensation | 34,811,634.78 | 21,502,353.08 | | Clinical Trial Fees | 32,706,571.52 | 16,302,470.38 | | Pre-clinical Research Fees | 12,834,117.32 | 4,649,270.64 | | Share-based Payment | - | 44,750,806.12 | | **Total** | **93,048,998.95** | **98,633,145.62** | Management Expense Composition (Jan-Jun 2022) | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Employee Compensation | 16,344,979.96 | 10,598,230.57 | | Consulting Fees | 6,166,571.02 | 3,266,665.38 | | Share-based Payment | - | 15,990,633.73 | | **Total** | **34,265,912.15** | **35,677,633.84** |

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2022 年第一季度报告 证券代码：688176 证券简称：亚虹医药 江苏亚虹医药科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同 期增减变动幅度(%) | | --- | --- | --- | | 营业收入 | 9,149.76 | 不适用 | | 归属于上市公司股东的净利润 | -47,294,447.66 | 不适用 | | 归属于上市公司股东的扣除非经常 性损益的净利润 | -55,231,306.27 | 不适用 | | 经营活动产生的现金流 ...

2021 年年度报告 公司代码：688176 公司简称：亚虹医药 江苏亚虹医药科技股份有限公司 2021 年年度报告 1 / 216 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且未实现盈利 √是 □否 2021 年度，公司归属于母公司所有者的净利润为-23,494.93 万元，归属于母公司所有者的扣 除非经常性损益的净利润为-19,523.31 万元。截至 2021 年 12 月 31 日，公司累计未弥补亏损为- 39,792.21 万元。 公司 2021 年度尚未盈利且存在累计未弥补亏损，主要是由于公司是一家全球化创新药公司， 自设立以来即从事新药研发活动，该类项目研发周期长，产品获批上市之前，需要在临床前研究、 临床开发、产品生产与控制等方面投入大量资金。公司持续投入大量研发费用导致公司累计未弥 补亏损不断增加。公司未来几年将存在持续大规模的研发投入，研发费用预计将持续处于较高水 平；同时公司未来产品上市后的商业化进展亦存在一定的不 ...